{"text": "There were 14 in-hospital deaths without relationship to GLN administration.", "user_data": {"pmid": "10338217"}}
{"text": "For respective comparisons of ALLO and AUTO transplants in the GLN and GLY hematologic groups and AUTO in the solid tumor groups, there were no significant differences in hospital stay, duration of stay after BMT, TPN days, neutrophil recovery >500/mm3, incidence of positive blood cultures, sepsis, mucositis, and diarrhea.", "user_data": {"pmid": "10338217"}}
{"text": "Possible reduction in need for TPN and a suggestion of improved long-term survival were associated with GLN.", "user_data": {"pmid": "10338217"}}
{"text": "Patients who received IT methotrexate had a mean Processing Speed Index that was 3.6 points lower, about one fourth of a standard deviation, than those who received triple IT therapy (P = .04) after analysis was adjusted for age, sex, and time since diagnosis.", "user_data": {"pmid": "19884541"}}
{"text": "Otherwise, the groups performed similarly on tests of full-scale intelligence quotient, academic achievement, attention/concentration, memory, and visual motor integration.", "user_data": {"pmid": "19884541"}}
{"text": "The association of treatment with measures of cognitive functioning was not modified by sex or age at diagnosis.", "user_data": {"pmid": "19884541"}}
{"text": "In the post-therapy period, there were no group differences in special education services, neurologic events, or use of psychotropic medications.", "user_data": {"pmid": "19884541"}}
{"text": "Proven, probable, or possible fungal infections occurred in 31% and 17% of the patients, respectively.", "user_data": {"pmid": "8156515"}}
{"text": "The risk of discontinuing prophylaxis due to fungal infection or toxicity increased with time in the study and was significantly greater for AMB (P = 0.02).", "user_data": {"pmid": "8156515"}}
{"text": "The median follow-up was 7 years (range, 2-10 years).", "user_data": {"pmid": "8453557"}}
{"text": "The overall survival (OS) for the two groups was 88% and 66%, respectively (P = 0.2).", "user_data": {"pmid": "8453557"}}
{"text": "The corresponding actuarial survival rates were 92% and 47%, respectively (P = 0.08).", "user_data": {"pmid": "8453557"}}
{"text": "In patients with low-grade histologic findings, the addition of adjuvant CHOP did not improve RFS (P = 0.6) or OS.", "user_data": {"pmid": "8453557"}}
{"text": "All relapses in this study were at sites remote from the initially involved areas, and in 5 of 11 patients (45%), there were recurrences 5 years or longer after initial treatment.", "user_data": {"pmid": "8453557"}}
{"text": "An interim analysis with 505 assessable patients and a median follow-up of 23 months showed a significant inferiority (according to sequential monitoring strategy) of the COPP/ABVD regimen in progression rate and freedom from treatment failure (FFTF) compared with the pooled results of both BEACOPP variants.", "user_data": {"pmid": "9850026"}}
{"text": "Differences in survival were not significant in sequential analysis.", "user_data": {"pmid": "9850026"}}
{"text": "The acute toxicity of baseline BEACOPP resembled that of COPP/ABVD; escalated BEACOPP showed increased but manageable hematologic toxicity.", "user_data": {"pmid": "9850026"}}
